predominance (3) . Rarely, familial cases have been reported (4, 5) . In the majority of patients the attacks last until the age of 10, but it has also been reported in adults (6) .
Pathogenesis
Autoinflammatory syndromes are a group of diseases characterized by inflammatory attacks that occur independently of autoreactive T lymphocytes or external triggering agents. The common termination of genes associated with these syndromes is interleukin (IL)-1β activation. Although the pathogenesis of PFAPA syndrome is not fully understood, it is evaluated in autoinflammatory syndromes. Studies have shown that IL-1β, IL-18, tumor necrosis factor-α, interferon (IFN)-γ from proinflammatory cytokines increase in the early phase of fever and IL-6 increases rapidly in the late phase (7) (8) (9) (10) (11) (12) . In contrast, levels of T-cell-associated cytokines IL-7, IL-17 and anti-inflammatory cytokines IL-10 and IL-4 decrease during exacerbation (8) . Dysregulation of IL-1 production from monocytes has been shown in patients (9) . In addition, increased expression of inflammation-associated genes (AIM2, CASP1) and IL-1 were detected during the episode (11) . In the fever episodes, dysregulation in natural immunity together with an increase in Th1 response, and reduction in Th2 response lead to changes in cytokine levels (8) (9) (10) 12) . Increased levels of monocytes, and decreased levels of eosinophiles and lymphocytes are observed during exacerbations (9, 10) .
Genetic background is one of the most controversial features of this syndrome. Although it is generally accepted as a sporadic disease, familial clustering suggests the presence of a possible hereditary component (13) . The link to genes associated with other autoinflammatory diseases has been investigated. Specifically observed was the MEFV mutation which plays a modifying role in PFAPA disease activation and it has been determined that with MEFV mutations the duration of attacks are irregular and shorter, the frequency of aphthous stomatitis and the need for glucocorticoid treatment is rare (14) .
In a large cohort study, 68 individuals and 14 families were enrolled to elucidate the genetic orientation of PFAPA syndrome. It was suggested that PFAPA is not a monogenic disease, but polygenic and/or is influenced by non-genetic factors (15) .
Clinical Findings
In a multicentre cohort analysis by Hofer et al. (16) , 301 patients with PFAPA were evaluated and clinical manifestations were reported. The study results reported so far are presented in Table I (2, 8, (17) (18) (19) (20) (21) . Fever starts suddenly with shudders. Body temperature ranges from 38.9 to 41.1 °C for 3-6 days. The period between fever episodes is around 28.2 days (26-30.4 days). The average number of attacks is 11.5 per year (2, 14) . Aphthous ulcer is frequently seen on the lips and in buccal mucosa, accompanied by fever attacks in 40-70% of cases, and heals without scarring (2, 16, 17) . Pharyngitis is detected in 90% of the patients. Exudative pharyngitis occurs in 41% of the cases (17) . Cervical adenopathy is associated with 78% of attacks, and 86% is bilateral (17) . Adenopathy is sensitive to touch. The clinical findings may also be accompanied by headache, muscle aches, diarrhea, arthralgia, cough and flu-like symptoms, and rash.
Laboratory Findings
There is no diagnostic laboratory test. Attacks may be diagnosed as tonsillitis or viral infection. Group A Streptococcus can be detected in 9.8% of cases in the throat culture (2) . PFAPA attacks do not respond to penicillin therapy. C-reactive protein (CRP) is high at the beginning of the attack, sedimentation may (20) . Procalcitonin does not increase like other acute phase reactants (22) . Serum immunoglobulin (Ig) levels are normal, IgD is normal or slightly elevated (20, 23) . All inflammatory parameters return to normal between the attacks (22) .
Differential Diagnosis
Cyclic neutropenia, whose attacks occur at specific intervals, is the most important differential diagnosis (2) . Cyclic neutropenic episodes occur every 18-24 days and the absolute neutrophil count falls below 500/mm 3 during the attack. Promyelocytic arrest is detected in the bone marrow, and attacks do not respond to steroid therapy (24) . Many monogenic autoinflammatory diseases may emerge with regular attacks and mimic or coincide with PFAPA syndrome. Especially in hyperimmunoglobulinemia D syndrome, familial Mediterranean fever and tumor necrosis factor receptorassociated periodic syndrome patients, PFAPA-like findings can be seen. Further research should be done if there are coughs, colds, severe abdominal pain, severe diarrhea, rash, arthritis and neuromuscular symptoms, increased acute phase response between episodes, and family history of periodic fever. In 2008, Gattorno et al. (19) formed a gaslini scoring system to help further investigation, which is recommended if the total score is higher than 1.32 in this scoring system, where abdominal pain, aphthous stomatitis, chest pain, presence of diarrhea, as well as the age at the onset of symptoms and family history are questioned.
Treatment
Since PFAPA syndrome is a self-limiting and benign disease, there is no clear treatment yet. The family and the physician should decide on the treatment together considering potential side effects, and social factors such as not being able to go to work and/or school in this febrile period (25) . Clinical experience has shown that paracetamol and nonsteroid anti-inflammatory drugs used in the treatment of PFAPA syndrome can not control symptoms other than fever.
Glucocorticoids: The administration of 1-2 mg/kg prednisolone at the onset of fever will control fever and pharyngitis, but not aphthous stomatitis and adenitis. This rapid response has a diagnostic feature that also helps to distinguish PFAPA syndrome from other periodic fever syndromes (6, 20) . However, glucocorticoids have been shown to shorten the time between attacks in 25% of patients (26) . Symptoms may recur within 48-72 hours after the first dose (27) . In this case, prednisolone 1 mg/kg on days 1 and 2; 0.5 mg/kg on day 2 and 3 can be repeated. There are studies recommending a single dose of betamethasone (0.3 mg/kg) at the onset of fever as an alternative to this treatment (23) . In some recent uncontrolled studies, low-dose (0.6 mg/ kg/g) prednisolone therapy has also been shown to improve the symptoms (24) . The most frequently reported side effects of glucocorticoid therapy are restlessness and sleep disturbance. These may be reduced if the prednisolone dose is given 4-6 hours before bedtime.
Tonsillectomy: Because PFAPA syndrome has a spontaneous remission, tonsillectomy, which has possible risks, is a controversial treatment. It is reported that in 1/3 of the patients symptoms repeat 0.5-10 years after tonsillectomy (25) . In another study evaluating the efficacy of the treatment, steroid therapy (90%), tonsillectomy (75%), tonsillectomy and adenoidectomy (86%) were found successful (2) . According to the results obtained from the meta-analysis performed by Burton et al. (28) , tonsillectomy (± adenoidectomy) was an effective treatment in children with PFAPA, and post-operative symptoms occurred four times more slowly. There was also a significant decrease in the number of PFAPA attacks and the use of corticosteroids after tonsillectomy. However, due to the disadvantages inherent in the surgical procedure, the choice of patients to be offered this treatment should be done carefully.
Among the less frequently applied therapies are colchicine, anti IL-1 and vitamin D treatments. In a study group in which colchicine treatment was given at 0.5-1 mg/ day together with prednisolone, there was a decrease in the frequency of attacks (18) . However, routine use of colchicine in the treatment of PFAPA is not recommended because of its short term effect, and the lack of studies on a sufficient number of patients (25) . IL-1β has been seen to elevate during PFAPA attacks. Acting on this, anakinra (recombinant IL-1β receptor antagonist) was used on a small group of patients, and there was a reduction in IFN-γ induced protein 10 and CXCL10 (chemokine, CXC motif, ligand 10) levels. Also clinical improvement was observed (9) .
Vitamin D: In addition to regulating calcium and phosphorus metabolism, it also has an immunomodulator effect. Vitamin D levels in PFAPA patients were found to be deficient and insufficient especially in winter. Vitamin D level is related with the number of attacks and CRP levels (29) .
Conclusion
Timely and accurate recognition of the most common PFAPA syndrome among periodic fever syndromes can be achieved with good patient follow-up. Treatment options should be selected specifically for the patient with the help of a strong parent-doctor relationship.
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